Evaluation of Ifosfamide/Mesna for Aggressive Meningeal Tumors (Malignant Meningioma, Hemangiopericytoma and Primary Nervous System Sarcoma), Phase II Study.

Patients must have a histologically confirmed diagnosis of malignant meningioma, hemangiopericytoma or primary CNS sarcoma. Submission of slides and block are mandatory. Patients must have measureable or evaluable disease by brain CT or MRI; patients may be on corticosteroids provided the dose is stable or decreasing for at least 7 days prior to obtaining CT or MRI scan; patients may have received no more than 2 prior chemotherapy regimens; prior RT is permitted however there must be documented progressive disease following radiation and all RT treatment must have been completed >= 4 weeks prior to registration; no prior ifosfamide; PS 0-2; no concomitant RT, chemo. or hormonal therapy; known HIV, benign meningioma or prior or current systemic sarcoma are not eligible.